Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence

Table 4

(a) Transition to edoxaban [17]. (b) Transition from edoxaban [17].

(a)

From	To	Recommendation
Warfarin	Edoxaban	Discontinue warfarin and start edoxaban when INR ≤2.5
Rivaroxaban, apixaban; Dabigatran		Discontinue current oral anticoagulant and start edoxaban at the time of the next scheduled dose of the other oral anticoagulant
Low-molecular-weight heparin (LMWH) Fondaparinux		Discontinue LMWH or fondaparinux and start edoxaban at the time of the next scheduled administrastion of LMWH or fondaparinux
Heparin Intravenous Infusion (IVI)		Discontinue the infusion and start edoxaban 4 hours later

(b)

From	To	Recommendations
Edoxaban	Warfarin	(1) Oral option: (i) For patients taking 60 mg of edoxaban, reduce the dose to 30 mg and begin warfarin concomitantly.; (ii) For patients receiving 30 mg of edoxaban, reduce the dose to 15 mg and begin warfarin concomitantly.; (iii) INR must be measured at least weekly and just prior to the daily dose of edoxaban to minimize the influence of edoxaban on INR measurements.; (iv) Once a stable INR greater or equal to 2.0 is achieved, edoxaban should be discontinued and the warfarin continued.; (2) Parenteral option: (i) Discontinue edoxaban and administer a parenteral anticoagulant and warfarin at the time of the next scheduled edoxaban dose.; (ii) Once a stable INR greater or equal to 2.0 is achieved, the parenteral anticoagulant should be discontinued and the warfarin continued.
	Apixaban; Rivaroxaban; Dabigatran	Discontinue edoxaban and start the other anticoagulant at the time of the next dose of edoxaban.
	LMWH Fondaparinux Heparin IV	Discontinue edoxaban and start the parenteral anticoagulant at the time of the next dose of edoxaban.